Bioventix PLC Stock

Equities

BVXP

GB00B4QVDF07

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:11 2024-05-03 am EDT 5-day change 1st Jan Change
4,325 GBX 0.00% Intraday chart for Bioventix PLC -2.26% +0.58%
Sales 2024 * 14M 17.58M Sales 2025 * 15.1M 18.96M Capitalization 226M 283M
Net income 2024 * 8M 10.04M Net income 2025 * 9M 11.3M EV / Sales 2024 * 15.7 x
Net cash position 2024 * 6M 7.53M Net cash position 2025 * 6.4M 8.04M EV / Sales 2025 * 14.5 x
P/E ratio 2024 *
26.3 x
P/E ratio 2025 *
24.3 x
Employees 12
Yield 2024 *
3.72%
Yield 2025 *
3.98%
Free-Float 91.92%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.23%
1 week-3.13%
Current month-2.58%
1 month-4.73%
3 months+0.23%
6 months+17.16%
Current year+0.81%
More quotes
1 week
4 250.00
Extreme 4250
4 500.00
1 month
4 250.00
Extreme 4250
4 800.00
Current year
4 179.00
Extreme 4179
5 100.00
1 year
3 402.00
Extreme 3402
5 100.00
3 years
2 880.00
Extreme 2880
5 100.00
5 years
2 590.00
Extreme 2590
5 100.00
10 years
26.51
Extreme 26.51
5 100.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 03-12-22
Director of Finance/CFO 65 20-06-30
Members of the board TitleAgeSince
Chairman 64 04-04-25
Chief Executive Officer 65 03-12-22
Director/Board Member 71 14-01-24
More insiders
Date Price Change Volume
24-05-03 4,325 0.00% 910
24-05-02 4,325 0.00% 1,737
24-05-01 4,325 +1.17% 4,510
24-04-30 4,275 -3.93% 11,930
24-04-29 4,450 0.00% 1,410

Delayed Quote London S.E., May 03, 2024 at 07:45 am EDT

More quotes
Bioventix plc is a United Kingdom-based biotechnology company. The Company specializes in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. It has created a sheep hybridoma technology to produce stable and productive cell lines that secrete sheep monoclonal antibodies (SMAs) of very high affinity. Its recombinant FAbs are modified to enable simple conjugation to enzymes (HRP, AP) or biotinylation or association as dimeric FAb2. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function, and drug abuse. It provides ELISA Kits to monitor human exposure to industrial pollutants. It supplies antibody products and services to clinical diagnostics companies.
Calendar
More about the company

Annual profits - Rate of surprise